Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630183 · ClinicalTrials.gov registry record · Phase 2
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Agenus.
- Active
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 20
- Study locations
NCT05630183: Active Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Agenus.
NCT05630183 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Agenus. The registered enrollment target is 81 participants, below the 180-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05630183, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Agenus.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Primary Outcome
Progression-free survival will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression, assessed by investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), or death, whichever occurs first.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Botensilimab
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- USC Norris Oncology - Newport Beach
- UCLA Health - Santa Monica Cancer Care - Santa Monica
Florida
- Florida Cancer Specialist South - Fort Myers
- Cancer Care Centers of Brevard - Palm Bay
- Florida Cancer Specialist North - St. Petersburg
New Jersey
- John Theurer Cancer Center at Hackensack - Hackensack
- Atlantic Health Systems, Morristown - Morristown
- Overlook Medical Center - Summit
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Arizona
- HonorHealth - Scottsdale
Delaware
- Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center - Newark
Illinois
- Illinois Cancer Specialists - Arlington Heights
Maryland
- Maryland Oncology Hematology - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2023-03-27 |
| Est. Completion | 2025-12-05 |
| Phase | Phase 2 |
What the registry record for NCT05630183 still lists
NCT05630183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 180-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT05630183 names 20 study sites across 13 states, led by California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05630183 about?
NCT05630183 is a clinical study titled "A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer". The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participan...
What is the current status of trial NCT05630183?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2023-03-27. Estimated completion is 2025-12-05.
What conditions does trial NCT05630183 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05630183?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT05630183?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05630183 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05630183's enrollment target sits among peer trials
81 8th of 20 higher than 13 of 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
ACTIVE NOT RECRUITING · Phase 2
-
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI